Pearl progresses with COPD metered dose inhaler; BioChemics osteoarthritis cream excels in trial;

> Pearl Therapeutics reports positive Phase IIb results from a study of glycopyrrolate, a long-acting muscarinic agonist delivered twice daily through a metered dose inhaler, for patients with moderate to severe chronic obstructive pulmonary disease. Release

> BioChemics says its Phase II study in Switzerland showed its transdermal ibuprofen-VALE cream was both effective and safe in treating osteoarthritis in the knee. Release

> A U.K. researcher says developers of drug delivery tech should focus more closely on drug carrier geometry to develop more accurate delivery systems, particularly on transport in the blood vessel. Story

> The Atlanta Business Chronicle profiled Alpharetta-based Carticept Medical, which is developing an ultrasound-guided, automatic injection device for patients with arthritis and joint pain. Story (sub. req.)

> Interarcia Therapeutics and Quintiles have inked a deal to develop Interarcia's ITCA 650, a once yearly, injection free, continuous, subcutaneous therapy to treat Type 2 diabetes. Release

> Sweden's Pharmalink will license Archimedes Pharma's TARGIT capsule drug delivery technology, which it will use as part of its treatment for the kidney disease IgA nephropathy. Release

> AngioScore, Inc. has begun enrollment patients in first-in-human trial of its drug-coated AngioSculpt scoring balloon catheter. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.